Cost-utility analysis of a structured medication review compared to usual care in Parkinson's disease.
Eur J Clin Pharmacol
; 79(2): 289-297, 2023 Feb.
Article
en En
| MEDLINE
| ID: mdl-36562830
ABSTRACT
PURPOSE:
For controlling symptoms in Parkinson's disease (PD) together with treating additional comorbidities, patients often face complex medication regimens, with suboptimal adherence, drug-related problems, and diminished therapy efficacy as a common consequence. A medication review could potentially tackle these issues, among others by optimizing drug treatment. Even if no change in clinical outcomes is observed, this intervention might decrease health care costs by reducing drug-related problems and hospital admissions. This study aimed to gain more insight in the health benefits and costs of a structured medication review (SMR) in PD.METHODS:
A cost-utility analysis was performed, based on a multicenter randomized controlled trial with 202 PD patients with polypharmacy. The intervention group received an SMR, whereas the control group received usual care. The intervention effect after 6 months of follow-up was presented as incremental quality-adjusted life years (QALY) using the EQ-5D-5L questionnaire. Costs were based on real-world data. Missing data was imputed using multiple imputation techniques. Bootstrapping was used to estimate the uncertainty in all health and economic outcomes.RESULTS:
The QALY gain in the intervention group compared to the control group was - 0.011 (95% CI - 0.043; 0.020). Incremental costs were 433 (95% CI - 873; 1687). When adapting a willingness-to-pay threshold of 20,000/QALY and 80,000/QALY, the probability of SMRs being cost-effective was 18% and 30%, respectively.CONCLUSION:
A community pharmacist-led SMR in PD patients in the current setting shows no apparent benefit and is not cost-effective after 6 months, compared to usual care. TRIAL REGISTRATION Netherlands Trial Register, NL4360. Registered 17 March 2014.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Enfermedad de Parkinson
Tipo de estudio:
Clinical_trials
/
Health_economic_evaluation
/
Qualitative_research
Aspecto:
Patient_preference
Límite:
Humans
Idioma:
En
Revista:
Eur J Clin Pharmacol
Año:
2023
Tipo del documento:
Article
País de afiliación:
Países Bajos